

# Clinical trials of betrixaban

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 thrombosis prevention

| Trial   | Treatments   | Patients | Trials design and methods       |
|---|--|----------|---------------------------------|
| <b>betrixaban vs enoxaparin</b>   |  |          |                                 |
| <a href="#">APEX , 2016</a><br>[NCT01583218]<br>n=3759/3754<br>follow-up: | betrixaban (at a dose of 80 mg once daily) for 35 to 42 days<br>versus<br>subcutaneous enoxaparin (at a dose of 40 mg once daily) for 104 days | -        | Parallel groups<br>double-blind |

More details and results :

- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- direct oral anticoagulant (DAO) for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q485>

## References

### APEX, 2016:

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016 May 27; [27232649]

Entry terms: PRT054021,